查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601228

臨床前 CRO 市場：按服務、應用和最終用戶分類 - 2025-2030 年全球預測

Preclinical CRO Market by Services (Bioanalysis & DMPK Studies, Toxicology Testing), Application (Cardiovascular Disease, Dermatology, Gastrointestinal), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年臨床前CRO市場價值為62.5億美元，預計到2024年將達到68.5億美元，複合年成長率為9.68%，到2030年將達到119.5億美元。

臨床前合約組織 (CRO) 透過外包從標靶識別到臨床前測試的廣泛研究服務，在藥物開發中發揮關鍵作用。臨床前 CRO 範圍涵蓋廣泛的服務，包括體外和體內模型、藥物動力學、毒理學和生物分析測試。隨著製藥公司尋求加速藥物開發過程，同時控制成本和應對複雜的監管環境，臨床前 CRO 的需求和應用變得越來越突出。最終用途範圍主要針對尋求專家指導和藥物發現和驗證設施的製藥和生物技術公司、學術研究機構和政府機構。

主要市場統計
基準年[2023] 62.5億美元
預測年份 [2024] 68.5億美元
預測年份 [2030] 119.5億美元
複合年成長率（%） 9.68%

臨床前CRO市場的成長是由研發投資增加、藥物發現方法的技術進步以及個人化醫療需求不斷成長等因素所推動的。新的機遇，例如將人工智慧和機器學習引入臨床前測試，可以顯著提高業務效率並提高臨床結果的可預測性。此外，鑑於人們對生物來源藥品的興趣日益濃厚，擴大與生技藥品和生物相似藥相關的服務也是一個潛在的成長領域。然而，它們也面臨著局限性和挑戰，包括市場競爭、不斷變化的監管要求以及動物測試的倫理問題。

創新的關鍵領域之一是替代測試模型的開發，例如器官晶片技術，它有望提供一種更道德、更精確的藥物測試方法。此外，進一步整合數位平台以改善資料管理並加強 CRO 和贊助商之間的合作也可以推動成長。市場的本質是動態和競爭的，重點是策略聯盟、併購，以增強我們的服務組合和全球影響力。為了在這一動態中取得成功，CRO 公司必須提供靈活和可自訂的服務，投資最尖端科技以滿足客戶不斷變化的需求，並在監管變化方面保持領先地位。

市場動態：揭示快速發展的臨床前 CRO 市場的關鍵市場洞察

供需的動態交互作用正在改變臨床前 CRO 市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 製藥和生物製藥公司活性化研發活動以開發新藥和治療方法
    • 製藥公司將藥物開發業務外包給 CRO 的趨勢日益明顯
    • 個人化藥物的開發日益受到關注
  • 市場限制因素
    • 與臨床前 CRO 服務相關的高成本和耗時的限制
  • 市場機會
    • 不斷進步的技術進步使臨床前研究更有效率和成本效益
    • 生技藥品（包括單株抗體、疫苗和細胞療法）臨床前研究的巨大潛力
  • 市場挑戰
    • 國際監管機構的嚴格規定和指南

波特五力：駕馭臨床前 CRO 市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解臨床前 CRO 市場的外部影響

外部宏觀環境因素在塑造臨床前CRO市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解臨床前 CRO 市場的競爭格局

對臨床前 CRO 市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣臨床前CRO市場供應商績效評估

FPNV定位矩陣是評估臨床前CRO市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 製藥和生物製藥公司增加研發活動以開發新藥和治療方法
      • 製藥公司將藥物開發業務外包給 CRO 的趨勢增加
      • 個人化醫療的發展日益受到關注
    • 抑制因素
      • 與臨床前 CRO 服務相關的高成本和耗時的限制
    • 機會
      • 技術進步使預調查更有效率且更具成本效益
      • 單株抗體、疫苗和細胞療法等生技藥品預研究的巨大潛力
    • 任務
      • 國際監管機構制定的嚴格法規和準則
  • 市場區隔分析
    • 服務：毒理學測試服務的使用正在迅速增加，重點關注安全和監管合方面。
    • 最終用戶：改變生物製藥公司使用臨床前 CRO 的方式
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章臨床前CRO市場：依服務分類

  • 生物分析和 DMPK 研究
  • 毒性試驗

第7章 臨床前 CRO 市場：依應用分類

  • 心血管疾病
  • 皮膚科
  • 胃腸道
  • 泌尿系統和女性健康
  • 血液學
  • 免疫疾病
  • 感染疾病
  • 代謝紊亂
  • 神經病學
  • 腫瘤學
  • 眼科
  • 呼吸系統疾病

第8章臨床前 CRO 市場：依最終使用者分類

  • 生物製藥公司
  • 政府和學術機構
  • 醫療設備公司

第9章美洲臨床前CRO市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區臨床前CRO市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲臨床前CRO市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • CRO公司TriApex完成君聯資本主導的C輪資金籌措
    • PsychoGenics 推出 eCube，一個用於新藥發現的人工智慧平台
    • 普魯士宣布大幅擴展臨床前研究和開發，以加速藥物安全決策
    • AmplifyBio 擴展了細胞療法的表徵並縮小了臨床前開發的差距
    • Clinchoice 透過收購 CRO 繼續擴張
    • QPS 在台灣開設新的預調查設施
    • CRO Avanir 收購明訊
    • Apax 收購 Porsolt 多數股權，支持公司的成長策略並成為臨床前服務的全球領導者
    • Cryoport 宣布與 Syneos Health 建立策略合作夥伴關係，以推進細胞和基因治療
    • Crown Biosciences 與 ERS ​​Genomics 宣布簽署全球 CRISPR/Cas9 基因組編輯專利授權協議
    • Domain Therapeutics 與 Exprycyte 簽署免疫腫瘤學領域合作協議
    • 賽揚擴大早期臨床藥理學部門
    • ClinChoice 在 E 輪融資中籌集 1.5 億美元
    • Hella Biolab 宣布與 Charles River 簽署全球獨家授權合約
    • IonsGate 臨床前服務和 InSilicoTrials 合作

公司名單

  • Phenos GmbH
  • Syneos Health, Inc.
  • Eurofins Scientific SE
  • Jubilant Biosys Ltd. byJubilant Pharmova Limited Company
  • Parexel International Corporation.
  • CTI Clinical Trial and Consulting, Inc.
  • Shanghai Medicilon Inc.
  • ICON PLC
  • Atuka Inc.
  • Gubra
  • MCI Group Holding SA
  • SGS SA
  • Immusmol SAS
  • PsychoGenics Inc.
  • Laboratory Corporation of America Holding
  • Hera Biolabs
  • IQVIA Inc.
  • Biotrofix, Inc.
  • Medpace Holdings, Inc.
  • Veristat, LLC
  • Crown Bioscience, Inc.
  • PharmaCircle LLC
  • PPD by Thermo Fisher Scientific Inc.
  • Sanofi SA
  • Celerion
  • BenchSci
  • SCiAN Services Inc.
  • Vimta Labs Limited
  • Transpharmation
  • Diag2Tec SAS
  • MD Biosciences
  • ImQuest BioSciences
  • QPS Holdings, LLC
  • Invivotek by Genesis Biotechnology Group, LLC
  • Intertek Group PLC
  • WuXi AppTec Co., Ltd.
  • 10x Genomics, Inc.
  • Novartis AG
  • AmplifyBio
  • Charles River Laboratories International, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Inotiv, Inc.
  • Bioserve Biotechnologies（India）PVT Ltd. by REPROCELL Inc.
Product Code: MRR-A339DAEFA51A

The Preclinical CRO Market was valued at USD 6.25 billion in 2023, expected to reach USD 6.85 billion in 2024, and is projected to grow at a CAGR of 9.68%, to USD 11.95 billion by 2030.

Preclinical Contract Research Organizations (CROs) play a crucial role in drug development by providing outsourced research services that range from target identification to preclinical testing. The scope of preclinical CROs encompasses a wide array of services, including in vitro and in vivo models, pharmacokinetics, toxicology, and bioanalytical testing. As pharmaceutical companies aim to accelerate their drug development processes while managing costs and navigating complex regulatory landscapes, the necessity and application of preclinical CROs have become more pronounced. The end-use scope predominantly covers pharmaceutical and biotechnology firms, academic research institutes, and government bodies seeking expert guidance and facilities for drug discovery and validation.

KEY MARKET STATISTICS
Base Year [2023] USD 6.25 billion
Estimated Year [2024] USD 6.85 billion
Forecast Year [2030] USD 11.95 billion
CAGR (%) 9.68%

Market growth for preclinical CROs is driven by factors such as increasing R&D investments, technological advancements in drug discovery methods, and an escalating demand for personalized medicine. Emerging opportunities, such as the adoption of AI and machine learning in preclinical studies, present avenues for significant operational efficiencies and improved predictability of clinical outcomes. Another potential growth area lies in expanding services related to biologics and biosimilars, given the rising interest in biologically-derived drugs. However, the market also faces limitations and challenges, including high competition, evolving regulatory requirements, and ethical concerns around animal testing.

One major area of innovation lies in the development of alternative testing models like organ-on-chip technologies, which promise a more ethical and precise approach to drug testing. Additionally, further integration of digital platforms to improve data management and increase collaboration between CROs and sponsors can also propel growth. The nature of the market is dynamic and competitive, with an increased focus on strategic partnerships, mergers, and acquisitions to enhance service portfolios and global reach. To thrive amidst these dynamics, CRO businesses should focus on offering flexible, customizable services and investing in cutting-edge technologies to meet the evolving needs of their clientele while staying ahead of regulatory changes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preclinical CRO Market

The Preclinical CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing R&D activities by pharmaceutical and biopharmaceutical companies to develop new drugs & therapies
    • Rising trend of outsourcing drug development activities to CROs by pharmaceutical companies
    • Growing focus on the development of personalized medicines
  • Market Restraints
    • High cost and time-consuming constraints associated with preclinical CRO services
  • Market Opportunities
    • Growing advances in technologies to enable more efficient and cost-effective preclinical research
    • High potential for preclinical research for biologics, including monoclonal antibodies, vaccines, and cell therapies
  • Market Challenges
    • Stringent regulations and guidelines set by international regulatory authorities

Porter's Five Forces: A Strategic Tool for Navigating the Preclinical CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preclinical CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Preclinical CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preclinical CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Preclinical CRO Market

A detailed market share analysis in the Preclinical CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preclinical CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preclinical CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Preclinical CRO Market, highlighting leading vendors and their innovative profiles. These include Phenos GmbH, Syneos Health, Inc., Eurofins Scientific SE, Jubilant Biosys Ltd. byJubilant Pharmova Limited Company, Parexel International Corporation., CTI Clinical Trial and Consulting, Inc., Shanghai Medicilon Inc., ICON PLC, Atuka Inc., Gubra, MCI Group Holding SA, SGS SA, Immusmol SAS, PsychoGenics Inc., Laboratory Corporation of America Holding, Hera Biolabs, IQVIA Inc., Biotrofix, Inc., Medpace Holdings, Inc., Veristat, LLC, Crown Bioscience, Inc., PharmaCircle LLC, PPD by Thermo Fisher Scientific Inc., Sanofi S.A., Celerion, BenchSci, SCiAN Services Inc., Vimta Labs Limited, Transpharmation, Diag2Tec SAS, MD Biosciences, ImQuest BioSciences, QPS Holdings, LLC, Invivotek by Genesis Biotechnology Group, LLC, Intertek Group PLC, WuXi AppTec Co., Ltd., 10x Genomics, Inc., Novartis AG, AmplifyBio, Charles River Laboratories International, Inc., F. Hoffmann-La Roche Ltd., Inotiv, Inc., and Bioserve Biotechnologies (India) PVT Ltd. by REPROCELL Inc..

Market Segmentation & Coverage

This research report categorizes the Preclinical CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Services, market is studied across Bioanalysis & DMPK Studies and Toxicology Testing.
  • Based on Application, market is studied across Cardiovascular Disease, Dermatology, Gastrointestinal, Genitourinary & Women's Health, Hematology, Immunological Disorders, Infectious Diseases, Metabolic Disorders, Neurology, Oncology, Ophthalmology, and Respiratory Disorders.
  • Based on End-User, market is studied across Biopharmaceutical Companies, Government & Academic Institutes, and Medical Device Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing R&D activities by pharmaceutical and biopharmaceutical companies to develop new drugs & therapies
      • 5.1.1.2. Rising trend of outsourcing drug development activities to CROs by pharmaceutical companies
      • 5.1.1.3. Growing focus on the development of personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and time-consuming constraints associated with preclinical CRO services
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing advances in technologies to enable more efficient and cost-effective preclinical research
      • 5.1.3.2. High potential for preclinical research for biologics, including monoclonal antibodies, vaccines, and cell therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and guidelines set by international regulatory authorities
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Services: Burgeoning usage of Toxicology testing services focusing on the safety and regulatory compliance aspects
    • 5.2.2. End-User: Evolving usage of preclinical CRO by biopharmaceutical companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Preclinical CRO Market, by Services

  • 6.1. Introduction
  • 6.2. Bioanalysis & DMPK Studies
  • 6.3. Toxicology Testing

7. Preclinical CRO Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Disease
  • 7.3. Dermatology
  • 7.4. Gastrointestinal
  • 7.5. Genitourinary & Women's Health
  • 7.6. Hematology
  • 7.7. Immunological Disorders
  • 7.8. Infectious Diseases
  • 7.9. Metabolic Disorders
  • 7.10. Neurology
  • 7.11. Oncology
  • 7.12. Ophthalmology
  • 7.13. Respiratory Disorders

8. Preclinical CRO Market, by End-User

  • 8.1. Introduction
  • 8.2. Biopharmaceutical Companies
  • 8.3. Government & Academic Institutes
  • 8.4. Medical Device Companies

9. Americas Preclinical CRO Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Preclinical CRO Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Preclinical CRO Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. CRO Company TriApex Completes Series C Financing Round Led by Legend Capital
    • 12.3.2. PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
    • 12.3.3. Proscia Announces Major Expansion in Preclinical R&D to Drive Faster Drug Safety Decisions
    • 12.3.4. AmplifyBio Expands Cell Therapy Characterization, Fills Gap in Preclinical Development
    • 12.3.5. Clinchoice Continues Expansion with CRO Acquisition
    • 12.3.6. QPS opens an additional preclinical research facility in Taiwan
    • 12.3.7. CRO Avania Acquires MAXIS
    • 12.3.8. Apax Acquires a Majority Stake in Porsolt to Support its Growth Strategy and Become a Global Leader in Preclinical Services
    • 12.3.9. Cryoport Announces Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies
    • 12.3.10. Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
    • 12.3.11. Domain Therapeutics and Explicyte Enter Partnership Agreement in Immuno-Oncology
    • 12.3.12. Celerion Expands Early Phase Clinical Pharmacology Units
    • 12.3.13. ClinChoice Raises USD 150 Million in Series E Round
    • 12.3.14. Hera BioLabs Announces Exclusive Global License With Charles River
    • 12.3.15. IonsGate Preclinical Services and InSilicoTrials Form Partnership

Companies Mentioned

  • 1. Phenos GmbH
  • 2. Syneos Health, Inc.
  • 3. Eurofins Scientific SE
  • 4. Jubilant Biosys Ltd. byJubilant Pharmova Limited Company
  • 5. Parexel International Corporation.
  • 6. CTI Clinical Trial and Consulting, Inc.
  • 7. Shanghai Medicilon Inc.
  • 8. ICON PLC
  • 9. Atuka Inc.
  • 10. Gubra
  • 11. MCI Group Holding SA
  • 12. SGS SA
  • 13. Immusmol SAS
  • 14. PsychoGenics Inc.
  • 15. Laboratory Corporation of America Holding
  • 16. Hera Biolabs
  • 17. IQVIA Inc.
  • 18. Biotrofix, Inc.
  • 19. Medpace Holdings, Inc.
  • 20. Veristat, LLC
  • 21. Crown Bioscience, Inc.
  • 22. PharmaCircle LLC
  • 23. PPD by Thermo Fisher Scientific Inc.
  • 24. Sanofi S.A.
  • 25. Celerion
  • 26. BenchSci
  • 27. SCiAN Services Inc.
  • 28. Vimta Labs Limited
  • 29. Transpharmation
  • 30. Diag2Tec SAS
  • 31. MD Biosciences
  • 32. ImQuest BioSciences
  • 33. QPS Holdings, LLC
  • 34. Invivotek by Genesis Biotechnology Group, LLC
  • 35. Intertek Group PLC
  • 36. WuXi AppTec Co., Ltd.
  • 37. 10x Genomics, Inc.
  • 38. Novartis AG
  • 39. AmplifyBio
  • 40. Charles River Laboratories International, Inc.
  • 41. F. Hoffmann-La Roche Ltd.
  • 42. Inotiv, Inc.
  • 43. Bioserve Biotechnologies (India) PVT Ltd. by REPROCELL Inc.

LIST OF FIGURES

  • FIGURE 1. PRECLINICAL CRO MARKET RESEARCH PROCESS
  • FIGURE 2. PRECLINICAL CRO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PRECLINICAL CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PRECLINICAL CRO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PRECLINICAL CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PRECLINICAL CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PRECLINICAL CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PRECLINICAL CRO MARKET DYNAMICS
  • TABLE 7. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PRECLINICAL CRO MARKET SIZE, BY BIOANALYSIS & DMPK STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PRECLINICAL CRO MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PRECLINICAL CRO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GENITOURINARY & WOMEN'S HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PRECLINICAL CRO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PRECLINICAL CRO MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PRECLINICAL CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PRECLINICAL CRO MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PRECLINICAL CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PRECLINICAL CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PRECLINICAL CRO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PRECLINICAL CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PRECLINICAL CRO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GOVERNMENT & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PRECLINICAL CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. JAPAN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 67. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. MALAYSIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 70. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. PHILIPPINES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 73. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. SINGAPORE PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 76. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. SOUTH KOREA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 79. TAIWAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. TAIWAN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 82. THAILAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. THAILAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 85. VIETNAM PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. VIETNAM PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 92. DENMARK PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. DENMARK PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 95. EGYPT PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. EGYPT PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 98. FINLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. FINLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 101. FRANCE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. FRANCE PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 104. GERMANY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. GERMANY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. ISRAEL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ISRAEL PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 110. ITALY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. ITALY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 113. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NETHERLANDS PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 116. NIGERIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. NIGERIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 119. NORWAY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. NORWAY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 122. POLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. POLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. QATAR PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. QATAR PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 128. RUSSIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. RUSSIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 131. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SAUDI ARABIA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH AFRICA PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 137. SPAIN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SPAIN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 140. SWEDEN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SWEDEN PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 143. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. SWITZERLAND PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 146. TURKEY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. TURKEY PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED ARAB EMIRATES PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. PRECLINICAL CRO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 155. PRECLINICAL CRO MARKET, FPNV POSITIONING MATRIX, 2023